Compare Crispr Therapeutics AG (CRSP) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Sea Limited — how do they compare? Crispr Therapeutics AG trades at $53.26 (market cap $4.88B), while Sea Limited trades at $95.49 (market cap $56.89B). The key difference: Sea Limited is far larger — about 11.7× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Sea Limited for 102 Days on average.
| CRSP | SE | |
|---|---|---|
Market Cap | $4.88B | $56.89B |
Volume | 2,861,747 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $188.00 |
52-Week Low | $44.34 | $78.16 |
Typical Hold Time | 77 Days | 102 Days |
Enterprise Value | $3.30B | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Sea Limited (SE) trades at $94.66, down 1.94% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. Analyst consensus remains strongly bullish with a $153.67 price target, representing 62% upside potential from current levels.
The stock presents a compelling growth opportunity with improving profitability and strong cash flow generation, though technical weakness and insider selling create near-term headwinds. Key risks include execution challenges in e-commerce profitability and competitive pressures in Southeast Asian markets. The disconnect between strong fundamentals and bearish technicals suggests potential for recovery if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
